See Why Travere Therapeutics Stock Moving Higher On Tuesday

Travere Therapeutics Inc TVTX has concluded a Type A meeting with the FDA related to sparsentan in focal segmental glomerulosclerosis (FSGS).
See: Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More Data.
Following the outcome of the Type A meeting, the Company intends to continue with its plan to provide the FDA with additional eGFR data from the ongoing DUPLEX Study in 1H of 2022.
At the time of the eGFR data cut, all patients remaining in the DUPLEX Study will have completed one year of treatment, and approximately 50% of patients will have completed two years of treatment.
The Company plans to submit an application for accelerated approval in the U.S. in mid-2022, pending additional supportive eGFR data.
The DUPLEX Study is continuing as planned.
Sparsentan is a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate.
Read Next: Sparsentan Showed Threefold Reduction In Proteinuria.
Price Action: TVTX shares are up 7.50% at $22.71 during the market session on the last check Tuesday.